Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room
NCT04726592 · Assistance Publique - Hôpitaux de Paris · PHASE3 · terminated · last registry update 2025-09-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “It has been determined that continuing with enrollments in this study is no longer justified due to the lack of significant impact on the expected outcomes.” | – | Registry record, Assistance Publique - Hôpitaux de Paris |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GABRA1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-05Results posted on the registry: University of Arkansas, a drug against GABRA1 (NCT06560918)
- 2026-04-06Also stopped (terminated): University of Oklahoma, Acamprosate (NCT00425711)
- 2024-12-17Results posted on the registry: Mayo Clinic, Acamprosate (NCT03818191)
- 2024-10-26Results posted on the registry: University of New Mexico, Ketamine + Methohexital (NCT04022226)
- 2024-09-25Also stopped (withdrawn): Henry Ford Health System, Acamprosate + Placebo (NCT06312800)
- 2024-09-19Results posted on the registry: National Cancer Institute (NCI), Cediranib + Sunitinib (NCT01391962)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision